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Abstract
The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal
carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations
and changes in gene expression, alongside microenvironmental and recognized histological alterations. Here, we
sought to comprehensively characterise the genomic and transcriptomic features of the MCF10 isogenic model
of breast cancer progression, and to functionally validate potential driver alterations in three-dimensional (3D)
spheroids that may provide insights into breast cancer progression, and identify targetable alterations in conditions
more similar to those encountered in vivo. We performed whole genome, exome and RNA sequencing of the
MCF10 progression series to catalogue the copy number and mutational and transcriptomic landscapes associated
with progression. We identified a number of predicted driver mutations (including PIK3CA and TP53) that were
acquired during transformation of non-malignant MCF10A cells to their malignant counterparts that are also
present in analysed primary breast cancers from The Cancer Genome Atlas (TCGA). Acquisition of genomic
alterations identified MYC amplification and previously undescribed RAB3GAP1–HRAS and UBA2–PDCD2L
expressed in-frame fusion genes in malignant cells. Comparison of pathway aberrations associated with progression
showed that, when cells are grown as 3D spheroids, they show perturbations of cancer-relevant pathways.
Functional interrogation of the dependency on predicted driver events identified alterations in HRAS, PIK3CA
and TP53 that selectively decreased cell growth and were associated with progression from preinvasive to invasive
disease only when cells were grown as spheroids. Our results have identified changes in the genomic repertoire in
cell lines representative of the stages of breast cancer progression, and demonstrate that genetic dependencies can
be uncovered when cells are grown in conditions more like those in vivo. The MCF10 progression series therefore
represents a good model with which to dissect potential biomarkers and to evaluate therapeutic targets involved
in the progression of breast cancer.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
The initiation and progression of breast cancer from the
transformation of the normal epithelium to carcinoma in
situ and invasive disease is a multifaceted process that
results in the acquisition ofmultiple genomic alterations,
including changes in genomic copy number, structural
rearrangements, acquisition of mutations, altered gene
expression, and pathway dysregulation [1–4]. The
transition through these states, i.e. non-invasive to
invasive disease, is a well-defined and staged process,
through which breast cancers progress to acquire the
capacity to grow, persist, and eventually spread to
secondary sites.
High-throughput molecular profiling of breast cancers
and their precursor lesions has revealed that they have
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distinct genomic and transcriptomic alterations [3,5–8];
however, matched preinvasive lesions and invasive
counterparts from the same patient are remarkably
similar [6–10], suggesting that the extent of genomic
heterogeneity is determined early in breast cancer
development. There is evidence suggesting that the
progression from in situ to invasive disease is not
exclusively driven by specific genomic aberrations in
the preinvasive cells, but is a result of paracrine inter-
actions of tumour cells with the surrounding stromal
environment [3,11–13].
The MCF10 progression series is a product of
the ‘normal’ mammary epithelial cell line MCF10A
that is spontaneously immortalised from the MCF10
mortal cell line (MCF10M), which originated from
benign fibrocystic disease [14]. As MCF10A cells are
non-tumorigenic, cells were HRAS-transformed to
produce MCF10neoT and MCF10AT1 cells [15,16]
(Figure 1A). MCF10AT1 cells were subsequently
serially passaged in vivo to produce carcinoma in situ
MCF10DCIS.com [17] and the invasive carcinoma
cells MCF10Ca1a, MCF10Ca1d and MCF10Ca1h
[18,19]. MCF10Ca1a and MCF10Ca1d are in vitro
clones derived from the same in vivo tumour, whereas
MCF10Ca1h is derived from a separate tumour
(Figure 1A). This series of cell lines therefore rep-
resents an isogenic model of disease progression, and
provides a useful tool for the investigation of molecular
changes during the progression of human breast neo-
plasia and the generation of tumour heterogeneity on a
common genetic background [19].
Numerous studies have characterised different cell
lines from the MCF10 progression series through the
use of genomic, transcriptomic and proteomic profil-
ing [20–26]. These have shown that alterations that
differ between the cell lines can identify drivers of
different stages of breast cancer progression. Indeed,
proteomic profiling has identified increased expres-
sion of AKT and STAT signalling in the invasive cell
lines, events that are also known to occur in primary
disease [26]. Similar studies also identified secreted
biomarkers that are known to be involved in metastasis
of non-invasive and invasive cells [27]. The model
has also proven useful in dissecting the role of poor
prognostic biomarkers, such as BRMS1 and FSP1, in
vitro [22,28], and for the identification and functional
assessment of novel biomarkers of progression from
ductal carcinoma in situ (DCIS) to invasive disease with
both three-dimensional (3D) culture and in vivo models
[21,23,29].
Here we sought to: (1) define the genomic charac-
teristics, at base pair resolution, of the MCF10 breast
cancer progression series of cell lines that are associ-
ated with different stages of progression; (2) determine
the enrichment of pathway alterations in the progression
from preinvasive to invasive disease; (3) establish an
in vitro functional screening tool using cancer cell line
spheroids, which more accurately recapitulate in vivo
models; and (4) use this platform as biological proof of
concept to identify potential driver genetic alterations of
breast cancer progression.
Materials and methods
Cell lines
The isogenic MCF10 cell line series includes the initial
untransformed normal cell line, MCF10A, the benign
proliferation stages (MCF10AT1 and MCF10NeoT),
the carcinoma in situ stage (MCF10DCIS.com), and
the invasive carcinoma stages (MCF10Ca1a cl1,
MCF10Ca1d cl1, and MCF10Ca1h). Cell lines were
kindly provided by The Barbara Ann Karmanos Can-
cer Institute (Detroit, MI, USA), except for MCF10A
cells, which were purchased from The American
Type Culture Collection (LGC, Teddington, UK), and
MCF10DCIS.com cells from Asterand (Royston, UK).
Cells were authenticated by short tandem repeat typing
with the Geneprint10 Kit (Promega, Southampton, UK),
and routinely tested for mycoplasma infection by use
of an enzyme-linked immunosorbent assay-based test
(MycoAlert Mycoplasma detection kit; Lonza, Basel,
Switzerland). Cells were grown as described previously
[30] and in supplementary materials, Supplementary
materials and methods.
Nucleic acid isolation
DNA was isolated with the DNeasy Blood and Tissue
kit (Qiagen, Crawley, UK), and RNA was extracted
with Trizol (Life Technologies, Paisley, UK), according
to the manufacturers’ instructions. Nucleic acids were
quantified using the Qubit Fluorometer assay (Life
Technologies), and RNA integrity was defined using
a Bioanalyzer (Agilent, Santa Clara, CA, USA). All
samples had an RNA integrity number of >9.
Exome sequencing
Genomic DNA (1 μg) was subjected to DNA capture
with the Human All Exome V4 XT kit (Agilent, Santa
Clara, CA, USA), and sequenced on 50% of a lane
on an Illumina HiSeq2500, resulting in a minimum
of× 109 median depth of coverage. Paired-end reads
in FASTQ format were aligned to the reference human
genome build GRCh37, by the use of Burrows–Wheeler
Aligner (BWA) [31]. Variants were identified with the
Genome Analysis Toolkit v3 (GATK) [32], and vari-
ant annotation was performed according to GATK Best
Practices recommendations with Refseq and excluding
decoy sequences [33,34]. Exome DNA sequencing was
also performed with the Ion Torrent AmpliSeq tech-
nology (Life Technologies), according to the manufac-
turer’s instructions (supplementary materials, Supple-
mentary materials and methods), with a median depth of
>100 for all samples. The Torrent Suite v4.0.2 pipeline
(Life Technologies) was used to align raw reads and
identify variants. Calls from the GATK were overlapped
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Figure 1. Spectrum of acquired alterations in the MCF10 progression series. (A) Diagrammatic representation of the generation of the
MCF10 progression series. Non-invasive cell lines are highlighted in grey, DCIS.com cell are highlighted in green, and invasive cell lines are
highlighted in red. Circled numbers represent the number of days for which cell lines were grown in vivo before replantation. (B) Matrix of
identified somatic mutations acquired from MCF10A cells that also occur in TCGA breast cancer data. Mutations were classified according
to membership of Cancer Gene Census (navy blue) [79], the results of the gene driver prediction algorithm FATHMM (purple) [61] and other
prediction algorithms (grey) are shown (see Materials and methods). (C) Heatmap of gains (red) and losses (blue) identified from GISTIC.
The genomic position is plotted along the x-axis, and samples are plotted on the y-axis. A heatmap of focal (<10Mb) amplifications and
homozygous deletions identified from GISTIC is shown. The colour scale bar depicts homozygous deletions to amplifications (–2 to +2).
Note the presence of focal amplification of MYC (8q24.21) acquired from MCF10neoT cells onwards. (D) Chromosome 8 plots of MCF10A,
MCF10neoT and MCF10Ca1a cells of log2-normalized sequencing reads (y-axis) plotted against base pair position cross chromosome
8. Green represents an amplification log2 ratio of >1.8. (E) Unrooted phylogenetic tree generated by neighbour joining of the MCF10
progression series based on variant data and whole arm chromosomal changes acquired from MCF10A cells onwards. Driver mutations and
chromosomal changes acquired are indicated in grey.
with calls from the Torrent Suite v4.0.2 pipeline to iden-
tify robust mutations. Candidate somatic mutations were
called on the basis of filtering of variants with minor
allele frequencies of>1% according to dbSNP build 132
andwith<5 supporting reads.Mutations associated with
progression in any cell line from MCF10neoT onwards
were subsequently annotated on the basis of calls by
Strelka [35], with MCF10As as the baseline compara-
tor and manual review with the Integrative Genomics
Viewer [36] to rule out the presence of reads support-
ing a given mutation in the ‘negative’ cell lines. Variants
were subsequently annotated with Annovar [37]. Muta-
tions were overlaid with annotated data from primary
breast cancers from The Cancer Genome Atlas (TCGA)
[38] and subjected to functional prediction algorithms
(supplementary materials, Supplementary materials and
methods). A subset of variants taken forward for func-
tional analysis were validated in all cell lines by Sanger
sequencing, as described previously [39].
Whole genome sequencing
Libraries for whole genome sequencing were prepared
with the NEBNext Ultra DNA Library Preparation
kit (New England Biolabs, Hitchin, UK) from 1 μg
of DNA, according to the manufacturer’s protocol.
Whole genome sequencing FASTQ files were aligned
to the human genome (hg19) with BWA [40], and copy
number variations were identified with the Patchwork
[41] and GISTIC algorithms [42], as described in
supplementary materials, Supplementary materials and
methods. DNA was also subjected to high-resolution
microarray comparative genomic hybridization (aCGH)
as described previously [43] and in supplementary
materials, Supplementary materials and methods.
Paired-end massively parallel RNA sequencing
RNA sequencing was performed with 100 ng of
ribosomal-depleted RNA from cell lines grown on
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plastic [two-dimensional (2D) and as spheroids] as
described previously [44] (see supplementary materials,
Supplementary materials and methods). RNA sequenc-
ing FASTQ files were aligned to the human genome
(GRCh37.73) with TopHat version 2.0.8b [45]. Reads
mapping to two or more locations were removed from
the analysis. Differential gene expression analysis
was performed with DESeq2, with an adjusted p-value
cut-off of≤0.01 [46]. Gene expression of the preinvasive
cells (MCF10A, MCF10AT1, and MCF10neoT) was
compared with that of the invasive cells (MCF10Ca1a,
MCF10Ca1d, and MCF10Ca1h). MCF10DCIS.com
cells were omitted from this analysis, given that they
form preinvasive lesions in vivo that spontaneously
become invasive [47]. Fusion genes were identified with
Chimerascan [48] and deFuse [49] algorithms. Pathway
enrichment was performed with ConsensusPathDB
[50].
Reverse transcription-quantitative PCR (RT-qPCR)
and Sanger sequencing validation
Reverse transcription was performed with Superscript
III (Invitrogen), with 500 ng of RNA per reaction, as
described previously [51] and in supplementary mate-
rials, Supplementary materials and methods. Sequences
were visualized by the use of 4Peaks (http://nucleobytes.
com/4peaks/). In-frame fusion genes were quantified
in the cell line series with RT-qPCR, and the abun-
dance of the fusion transcript relative to β-actin mRNA
(ACTB) was calculated with the delta-delta CT method.
Primer sequences are listed in supplementary materials,
Table S1.
Small interfering RNA (siRNA) screen
Genes were chosen to be screened with siGENOME
smartpool siRNA (GE Healthcare, Little Chalfont,
UK) targeting wild-type genes in 96-well spheroid
assays, based on the presence of either: (1) recur-
rent amplifications and homozygous deletions, or (2)
non-synonymous coding mutations in the progression
series. Alterations were chosen that were also present
in primary tumours assessed in METABRIC [52] and
aCGH studies [53–55] for copy number alterations,
and from TCGA and other published studies at a fre-
quency >0.5% for somatic mutations [56–60]. For
amplifications and homozygous deletions, those that
are either known drivers or predicted drivers (for ampli-
fications) as assessed from a significant correlation of
amplification with gene expression [55] were selected.
For mutations, those that are known to be drivers or
predicted to be drivers from the prediction algorithm
FATHMM [61] were triaged for functional assessment.
Three-dimensional spheroid cultures
Five thousand cancer cells per well of a 96-well
low-attachment plate (Corning, Amsterdam, The
Netherlands) were reverse-transfected with 37.5 nM
siGENOME smartpool siRNA (GE Healthcare) or
siControls [positive (ubiquitin B) and negative (pool
1)] by the use of Lullaby reagent (Oz Biosciences,
Marseille, France) in 180 μl of cold culture medium, as
described previously [62]. Spheroid area was calculated
with Celigo S (Nexcelom, Lawrence, MA, USA), and
viability was measured with the CellTiter-Glo assay
(Promega). Relative growth was calculated relative
to siControl. Hits were scored as >1.2 for increased
spheroid growth and as <0.8 for reduced cell growth
(see supplementary materials, Supplementary materials
and methods).
Transfections of mammalian cells on plastic
Two thousand five hundred cancer cells per well of
a 96-well plate (Sigma-Aldrich, Dorset, UK) were
reverse-transfected with 37.5 nM siGENOME siRNA
by the use of Lullaby reagent (Oz Biosciences),
as described previously [54] and in supplementary
materials, Supplementary materials and methods.
Immunohistochemistry of spheroid cultures
Spheroids were grown for 7 days, and fixed in 3.8%
formaldehyde for 30min, washed with phosphate-
buffered saline three times, and stored at 4 ∘C. Spheroids
were then pooled, dehydrated, embedded in paraffin,
and sectioned. The spheroid sections were then deparaf-
finized with xylene, rehydrated, microwaved, and
incubated overnight with primary antibodies against
Ki67, TP53, and pAKT (see supplementary materials,
Supplementary materials and methods).
Statistical analyses
p-Values of <0.05 (heteroscedastic, two-sided) were
considered to be statistically significant for comparisons
of the siRNA screen.
Data availability
Raw whole genome, exome and RNA sequencing
data have been deposited in the NCBI Sequence Read
Archive under the accession number PRJNA308098.
Results
Genomic alterations associated with breast cancer
progression
To better understand the role of genomic and tran-
scriptomic alterations in breast cancer progression, we
performed whole exome, low-depth whole genome
and RNA sequencing of the MCF10 progression series
(Figure 1A) to comprehensively define the repertoire
of mutations, copy number alterations, expressed
fusion genes and transcriptional alterations. Whole
exome sequencing was performed with both capture
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and amplicon-based sequencing at an average depth
of× 100. This identified 7275 coding non-synonymous
variations [single-nucleotide variants (SNVs)] in
MCF10A, 7327 in MCF10neoT, 7336 in MCF10AT1,
7364 in MCF10DCIS.com, 7354 in MCF10Ca1a, 7351
in MCF10Ca1d, and 7358 in MCF10Ca1h. Taking
MCF10A cells as the baseline, we identified muta-
tions in 196 genes that were acquired in the malignant
cell lines (i.e. not present in MCF10A non-malignant
cells; supplementary materials, Table S2), including
64 genes that also occur in TCGA and other pub-
lished DNA sequencing studies [56–60] (Figure 1B).
These included a PIK3CA hotspot mutation (H1047R)
acquired in MCF10DCIS.com cells and maintained in
the invasive cell lines MCF10Ca1a and MCF10Ca1h
(in agreement with previous reports [63]), and novel
convergent mutations in TP53 in MCF10Ca1a and
MCF10Ca1h cells. We next defined the presence of
relevant breast cancer predicted driver gene mutations
that were acquired in the malignant cells by annotating
the variants with a combination of functional prediction
algorithms (see Materials and methods) and the specific
cancer driver prediction algorithm FATHMM [61]. This
analysis revealed 53 mutations that were predicted to
disrupt protein function, and seven predicted cancer
driver mutations. These encompassed four predicted
cancer driver mutations that were acquired during
transformation of non-malignant MCF10A cells to
malignant DCIS.com cells (HRAS, EPHA7, MAP3K12,
and PCSK5), and three that were acquired during trans-
formation of MCF10DCIS.com cells to invasive cells
(MCF10Ca1a and MCF10Ca1h) (PTPRD, TP53, and
VSP13A) (Figure 1E; supplementary material, Figures
S1 and S2). Furthermore, 57% of all variants were
expressed at the RNA level (supplementary material,
Table S2).
Somatic copy number alterations associated
with progression
We used low-depth [on average, ×7 (range of coverage,
×6–9] whole genome sequencing to characterise the
repertoire of copy number alterations of cell lines within
the progression series. Consistent with previous obser-
vations [24,63], MCF10A cells had high-level gains
of 1q, gains of 5q, 8q, 19q, and 20q, and homozygous
deletion of 9p encompassing CDKN2A/B (supplemen-
tary material, Figure S3). Indeed, the other cell lines
were comparable, with high-level focal amplification
of 8q24.21, encompassing MYC, 10q22.1–q22.2, and
17p11.2 (Figure 1D; supplementary material, Table
S3). They did not have gain of 1q, and were there-
fore probably derived from a clone of the parental
line that had normal 1q (Figure 1C). Interestingly,
MCF10DCIS.com cells had both the gain of 1q seen in
the parentalMCF10A cells and the three focal high-level
amplifications. A number of homozygous deletions
were acquired during progression, including 8p23.1
(MCF10DCIS.com, MCF10Ca1a, and MCF10Ca1d),
12p13.2 (MCF10AT1, MCF10DCIS.com, and
MCF10Ca1a) and 22q12.2 (MCF10neoT, MCF10AT1,
MCF10DCIS.com, MCF10Ca1a, and MCF10Ca1d)
(Figure 1C; supplementary material, Figures S3
and S4 and Table S3). In addition, acquisition of
a focal intragenic homozygous deletion of RUNX1
(MCF10DCIS.com, MCF10Ca1a, and MCF10Ca1d)
was identified (in agreement with previous reports [63]).
Fusion gene transcripts associated with progression
Previous studies have reported that breast cancers
can show extensive large-scale genomic rearrange-
ments [64], and have documented the presence of
expressed fusion genes that drive the malignant pheno-
type of the cells and present therapeutic opportunities
[43,65]. RNA sequencing analysis of the MCF10
progression series identified expressed fusion genes
in MCF10DCIS.com (n= 1), MCF10Ca1d (n= 1)
and MCF10Ca1h (n= 2) that were identified by both
deFUSE [49] and Chimerascan [48] fusion gene detec-
tion algorithms (supplementary material, Table S4).
These included two fusion transcripts predicted to result
in novel functional proteins (i.e. in-frame) that were not
present in MCF10A cells, namely an interchromosomal
fusion involving RAB3GAP1 and HRAS, detected in
MCF10DCIS.com and MCF10Ca1d cells, and an intra-
chromosomal fusion on chromosome 19q involving
UBA2 and PDCD2L in MCF10Ca1h cells (Figure 2A,
B). Validation of the fusion transcripts with RT-qPCR
and Sanger sequencing demonstrated that the in-frame
RAB3GAP1–HRAS fusion was present in all cell lines
that had been subjected to HRAS transformation (i.e.
from MCF10AT1 onwards), whereas UBA2–PDCD2L
was only seen in MCF10Ca1h cells (Figure 2C, D;
supplementary material, Table S4). Neither fusion was
detected in the control cell line MCF7. Furthermore,
the levels of RAB3GAP1–HRAS transcript expression
increased from MCF10neoT cells across the progres-
sion series, with MCF10Ca1d cells showing the highest
expression. This observation mirrored the HRAS gene
expression levels detected in the RNA sequencing
data (Figure 2E), suggesting that the differences in
HRAS expression may be attributable to the presence
of the fusion gene. Interestingly, the reciprocal fusion
HRAS–RAB3GAP1 was detected in MCF10DCIS.com
cells; however, this was not predicted to result in
a functional protein. Mining of the TCGA Fusion
gene Data Portal (http://54.84.12.177/PanCanFusV2/)
[66] and other published fusion datasets in breast
cancer [43,64,65] identified two additional in-frame
fusion genes involving RAP3GAP1 in breast cancer
(RAB3GAP1–ACMSD and RAB3GAP1–MAP4K3). An
in-frame HRAS fusion gene was identified in a head
and neck primary tumour (RNH1–HRAS) that leads to
increased levels of HRAS expression [66]; however,
no additional HRAS fusion genes were detected in pri-
mary breast cancers. An out-of-frame UBA2–PDCD2L
fusion was detected in a primary ovarian cancer, but
none was observed in breast cancer.
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Figure 2. Identification of expressed fusion genes in the MCF10 progression series. (A) Cartoon representation of genomic location,
orientation and architecture of the expressed RAB3GAP1–HRAS fusion gene. Representative RNA sequencing reads spanning the fusion
are also displayed. The RT-qPCR product was Sanger-sequenced; confirming the fusion junction, and a representative chromatogram from
MCF10Ca1d cells is shown. (B) Cartoon representation of genomic location, orientation and architecture of the expressed UBA2–PDCD2L
fusion gene. Representative RNA sequencing reads spanning the fusion are also displayed. The RT-qPCR product was Sanger-sequenced,
confirming the fusion junction, and a representative chromatogram fromMCF10Ca1h cells is shown. (C) Bar plot showing relative expression
of the RAB3GAP1–HRAS fusion gene in the MCF10 progression series detected by RT-qPCR. (D) Bar plot showing relative expression of the
UBA2–PDCD2L fusion gene in the MCF10 progression series detected by RT-qPCR (E) Bar plot of normalized reads of HRAS in the MCF10
progression series from RNA sequencing.
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Pathway alterations associated with breast cancer
progression
We next sought to assess the differences in gene expres-
sion during progression from preinvasive to invasive
disease. Differential gene expression of preinvasive
cell lines (MCF10A, MCF10AT1, and MCF10NeoT)
and invasive cell lines (MCF10Ca1a, MCF10Ca1d,
and MCF10Ca1h) identified 236 significantly differ-
entially expressed genes [false discovery rate (FDR)
p-value of <0.01; DEseq2] (Figure 3A; supplementary
material, Table S5). These genes were enriched in
pathways involved in platelet amyloid precursor protein
processing, senescence, autophagy, and arachidonic
acid metabolism (Figure 3B; supplementary material,
Table S6). Previous studies have demonstrated that the
MCF10 progression series behave differently when
grown in 3D culture, and provide a useful model for
studying driver alterations associated with oncogenic
transformation [67,68] and disease progression [69,70].
Indeed, cell lines from the progression series formed
spheroids, and showed good growth kinetics and posi-
tive histological staining of the proproliferative markers
Ki67 and phospho-AKT (supplementary material,
Figure S5). To further evaluate functional pathways that
may be dysregulated in breast cancer progression, in
cells grown in more in vivo-like conditions [62], we per-
formed RNA sequencing of the series of cell lines grown
as 3D spheroids. This analysis identified 1022 genes
that were differentially expressed between preinvasive
and invasive cell lines (supplementary material, Table
S5). Functional annotation of these genes identified
significant over-representation of pathways involved
in nuclear receptor signalling, epidermal growth factor
receptor (EGFR) signalling, ErbB receptor signalling,
fibroblast growth factor receptor (FGFR) signalling,
signal transduction, integrin signalling, and extracellu-
lar matrix organization (Figure 3A, B; supplementary
material, Table S6). These findings indicate that more
cancer-relevant pathways are active when cells are
grown in a 3D environment, possibly reflecting the way
in which the cells were selected for in vivo when they
were generated [19].
Functional characterisation of driver alterations
upon progression
Given our observations that, when grown in spheroid
cultures, the MCF10 cell line series show enrichment
of cancer-relevant pathways associated with progres-
sion to invasive disease, we sought to functionally test
which genomic alterations (amplifications, homozygous
deletions, and mutations) that are also seen in primary
breast cancers (Figure 3C; see Materials and methods)
would be driving the growth of these cells. Cell lines
were optimized for siRNA-mediated gene depletion,
whereby ablation of the genes encoding the tumour sup-
pressor phosphatase and tensin homolog and ubiquitin
B resulted in increased and decreased spheroid growth
relative to control siRNA, respectively (supplementary
material, Figure S5). A siRNA-based screen of 18 genes
identified three that constitute potential driver events,
namely PIK3CA (p= 0.0485, t-test), HRAS, and TP53
(p< 0.0001, t-test), and that, when silenced, decreased
spheroid growth and were associated with genomic
status (Figure 3D; supplementary material, Table S7).
Deconvolution of the siRNA oligonucleotide pools
showed that all of these genes were oncogenic drivers,
resulting in decreased spheroid growth when silenced
(supplementary material, Figure S6). These included
PIK3CA, whereby cells with an H1047R activating
mutation showed selective dependency on PIK3CA
silencing (Figure 4A). In addition, PIK3CA mutant
cells were also selectively dependent on AKT1 silencing
(p= 0.046, t-test), perhaps reflective of the subsequent
increased AKT1 activation, (Figure 4A; supplementary
material, Figures S5 and S6); however, this appeared
to be an effect specific to cells grown as spheroids, and
was not observed in traditional 2D culture (Figure 4B;
supplementary material, Table S7). Furthermore, the
oestrogen receptor-negative breast cancer cell line
BT20, which harbours an H1047R PIK3CA mutation,
showed a similar effect (Figure 4B). Moreover, breast
cancer cell line spheroids showed dependency on
PIK3CA according to their PIK3CA status, with mutant
MCF7 and T47D cells (harbouring E575K and H1047R
PIK3CA mutations, respectively) being sensitive to
PIK3CA silencing, and MDA-MB-231 cells (wild type)
showing no change in viability after PIK3CA silencing.
It is tempting to posit that this is due to the maintenance
of AKT activity under unfavourable conditions imparted
by the spheroid architecture, as spatial AKT activity
was observed in the preinvasive cell lines, whereas
stable and high phospho-AKT staining was observed
in the invasive cell line spheroids that harboured the
activating mutation in PIK3CA (Figure 4E).
Interestingly we observed two independent SNVs in
MCF10Ca1a andMCF10Ca1h cells in theDNA-binding
domain of TP53, suggestive of convergent evolution.
TP53 silencing in the progression series significantly
correlated with smaller spheroid size in mutant cells,
suggesting that these mutations act in an oncogenic
manner (p= 0.0051, t-test). Moreover, there was
a significant dependency on TP53 associated with
increased progression (preinvasive versus invasive cells;
p= 0.0021, t-test), regardless of mutation status, that
appeared to correlate with increased nuclear accumu-
lation of TP53 protein in these cells (Figure 4D, E). It
is of note that all cell lines showed sensitivity to MYC
silencing, suggesting that cells are dependent on MYC
transcriptional activity independently of amplification
status (Figure 4D).
Given that MCF10A cells underwent HRAS trans-
formation to produce subsequent cell lines, we tested
whether cells would still be dependent on oncogenic
RAS signalling for their survival further along the course
of progression for cell survival. Indeed, silencing of
HRAS reduced spheroid growth of all cells subsequent
to MCF10A (Figure 5A); however, this association
appeared to be significantly correlated with expression
of the RAP3GAP1–HRAS fusion gene (r= –0.7857,
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Figure 3. Evaluation of pathways and driver alterations in spheroid cultures. (A) Volcano plots showing the differentially expressed
transcripts between preinvasive and invasive cells from the MCF10 progression series cultured under both 2D and 3D conditions. Red:
FDR p-values of <0.01. (B) Bar plot showing the significantly over-represented pathways (ConsensusDb q-value of <0.01) from (A). (C)
Schematic of gene selection for the siRNA screen. (D) Matched heatmaps of genomic status (mutation, amplification, and homozygous
deletion); results of spheroid growth after siRNA-mediated silencing and gene expression. Relative spheroid growth was measured according
to the survival fraction of treated cells relative to siControl. Hits were triaged as a relative survival fraction as compared with non-targeting
control of <0.8 or >1.2. Gene expression is the log2 median centred normalized reads from the RNA sequencing data.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 315–328
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Figure 4. Functional validation of dependency on driver events in the MCF10 progression series. (A) Progression series cell lines were
reverse-transfected with siRNAs against PIK3CA and AKT1, and with a non-targeting control. Spheroids were formed after 24 h in
low-attachment plates, and the medium was topped up every 3 days. After 7 days, spheroid viability was determined with Cell Titre Glo. (B)
DCIS.com and BT20 cell lines were reverse-transfected with siRNAs targeting PIK3CA and UBB, and with a non-targeting control, under both
2D and 3D conditions. The medium was topped up every 3 days. Viability was determined with Cell Titre Glo. Statistical comparisons were
performed with Student’s t-test (*p≤ 0.05). (C) MDA-MB-231, MCF7 and T47D cell lines were reverse-transfected with siRNAs targeting
PIK3CA and UBB, and with a non-targeting control, under 3D conditions. The medium was topped up every 3 days, and spheroid viability
was determined with Cell Titre Glo. Statistical comparisons were performed with Student’s t-test (*p≤ 0.05). (D) Progression series cell
lines were reverse-transfected with siRNAs against TP53 and MYC , and with a non-targeting control. Spheroids were formed after 24 h in
low-attachment plates, and the medium was topped up every 3 days. After 7 days, spheroid viability was determined with Cell Titre Glo. (E)
The progression series was grown for 7 days. The medium was topped up every 3 days. After 7 days, spheroids were fixed with formaldehyde,
embedded, sectioned, and stained for phospho-AKT (P-AKT) (473) and total TP53. Representative images are shown. Scale bar: 100 μm.
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p= 0.0480, Spearman rank correlation) rather than on
total HRAS expression (r= –0.5714, p= 0.2, Spearman
rank correlation), and, in a similar manner to PIK3CA
and AKT1, seemed to be more specific to cells grown as
spheroids (supplementary material, Figure S5). Specific
silencing of the RAB3GAP1–HRAS fusion gene, how-
ever, had no effect on spheroid growth (Figure 5A, B),
perhaps indicative of the subclonal nature (as evidenced
by the low percentage of the transcript involved in the
fusion, i.e. isoform fraction) of the cells in which the
fusion was detected with RNA sequencing (supplemen-
tary material, Table S4).
Discussion
Here, we have performed a comprehensive analysis of
both the genomes (at base pair resolution) and transcrip-
tomes of the MCF10 cell line series that represent dif-
ferent stages of breast cancer progression when grown
in vivo, and have demonstrated that these cell lines har-
bour relevant driver alterations seen in primary breast
cancers, and represent a good model for studying breast
cancer progression with in vitro spheroid models.
Overall, the patterns of genomic copy number alter-
ations are similar between the cell lines; however,
there are key differences, suggestive of subclonal selec-
tion from the parental MCF10A cells. In particular, at
base pair resolution, the number of mutations varied
across cell lines, with a number of key driver muta-
tions being selected for at different stages of progres-
sion. These included a PIK3CA hotspot mutation in
MCF10DCIS.com cells that leads to increased AKT
signalling, and TP53 mutations in the more aggressive
invasive cell lines MCF10Ca1a and MCF10Ca1h [71],
as shown by increased nuclear accumulation of TP53
protein in these cells. We identified a number of muta-
tions that were clonally selected through progression for
which the allele fraction differed in the different cell
lines. It may be the case that such alterations are merely
passengers (i.e. do not confer a selective advantage to the
cells); however, they may provide a growth advantage at
different stages of progression, which is in agreement
with recent studies on triple-negative breast cancers,
where genuine driver alterations have been shown to be
subclonal and heterogeneously distributed [59]. At the
copy number level, focal high-level MYC amplification
was acquired in the malignant cell lines, as previously
reported [63]; however, it was not seen in MCF10A
cells, which harboured gain of the entire arm of 8q.
This finding is in agreement with other reports show-
ing gain ofMYC to be an initiating event in this cell line
panel, rather than focal amplification [72]. Indeed,MYC
amplification has been associated with a poor prog-
nosis [73,74], and is often acquired in metastatic dis-
ease [75,76]. However, all cells in the progression series
appeared to be sensitive to MYC silencing. Although
the majority of the cell lines appeared to be derived
from a clone lacking 1q gain, the presence of 1q gain
in MCF10DCIS.com cells may alternatively be a result
of isochromosome 1q being lost in culture.
Consistent with previous observations that members
of the MCF10 progression series behave differently
when grown in 3D culture [69,70], we found a number
of distinct differentially regulated pathways associated
with progression when cells were grown in spheroids as
compared with traditional 2D culture, perhaps reflecting
the nature of the nutrient and oxygen gradients in these
models [62]. Indeed, functional assessment of recur-
rent alterations identified oncogenic dependencies that
were only observed when assessed in spheroid mod-
els, including a selective dependency on PIK3CA sig-
nalling in cells harbouring an H1047Rmutation that was
corroborated in additional breast cancer cells harbour-
ing the H1047R mutation. Indeed, the H1047R muta-
tion has been shown to promote metabolic adaption by
increasing de novo lipogenesis [77], a feature observed
in aggressive cancers.
Through exome sequencing, we identified indepen-
dent non-synonymous coding mutations in TP53 in
the MCF10Ca1a and MCF10Ca1h cell lines. Consis-
tent with observations that TP53 mutations can be late
events in breast cancer progression [59] and are asso-
ciated with a poor prognosis [78], it has been shown
that these sublines can spontaneously metastasise when
grown in vivo [19]. Interestingly, in all the invasive
cells (MCF10Ca1a-1 h), increased nuclear TP53 protein
accumulation was observed, which correlated with sen-
sitivity to TP53 silencing, suggesting that TP53 dysreg-
ulation is associated with increased cellular invasiveness
and an oncogenic dependency in this model.
In addition to the identification of mutations associ-
ated with progression, we also identified two in-frame
fusion genes in the cell line series, included a HRAS
fusion that was acquired in MCF10neoT cells, which
were transformed by oncogenic HRAS, and was main-
tained in all subsequent cell lines. This fusion gene
joins the promoter of RAB3GAP1, which encodes a
GTPase-activating protein, to exon 3 ofHRAS. Although
it is interesting to speculate that this fusion gene would
also lead to selective HRAS dependency, given an
observed correlation of HRAS oncogenic dependency
and expression of the fusion gene, we observed no
effect on spheroid growth with selective inhibition of
the fusion gene. This may be because the fraction of
fusion transcript as compared with that wild-type tran-
script represents ∼1% of all HRAS reads. As no addi-
tional HRAS fusion genes were observed on analysis of
published RNA sequencing data, this fusion most likely
represents a consequence of HRAS v12 transformation.
Our study, although comprehensive, is not without
limitations. HRAS mutation is not a common genetic
alteration in human breast cancer, so the cell line series
model might not accurately reflect the tumorigenic
process in human breast cancers. This is exemplified by
the identification of a fusion gene involving HRAS in
the model and the lack of such fusion genes in primary
breast cancer. Although exome sequencing identified
the acquisition of mutations in the malignant cells, we
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Figure 5. Functional validation of dependency on TP53 and HRAS in the MCF10 progression series. (A) Progression series cell lines were
reverse-transfected with siRNAs against HRAS and RAB3GAP1–HRAS, and with a non-targeting control. Spheroids were formed after 24 h
in low-attachment plates, and the mediumwas topped up every 3 days. Spheroid viability was determined with Cell Titer Glo. (B) MCF10Ca1a
cells were reverse-transfected with single and pooled siRNAs targeting HRAS and RAB3GAP1–HRAS, and with a non-targeting control, for
72 h. HRAS expression and RAB3GAP1–HRAS expression were determined with RT-qPCR. Expression was normalized to loading controls
B2M and β-actin (ACTB).
cannot rule out the possibility that these are present at
very low subclonal populations in the parental MCF10A
cells, given that we did not perform high-depth targeted
resequencing. Nevertheless, through exome sequencing
with an average depth of× 100, we observed clonal
selection of alterations across different cell lines, sug-
gesting that MCF10A cells are oligoclonal. Although
our copy number data support this, the low depth of
coverage may also limit the detection of subclonal
events. Our triage of genomic alterations for functional
assessment mainly identified mutational events and
homozygous deletions rather than amplifications that
were representative of primary breast cancers. This may
be due to our triage strategy; however, it is known that, in
general, triple-negative breast cancers lack many recur-
rent amplification events [59]. Moreover, genomic alter-
ations tested that did not cause a difference in spheroid
growth may score in additional assays, and may warrant
further testing. In addition, functional assessment of
differentially expressed genes may provide further
insights into the drivers of progression in this model.
In conclusion, comprehensive characterisation of the
MCF10 isogenic progression series has identified a
number of driver alterations that are associated with
progression from preinvasive to invasive cellular pheno-
types that model the genomic alterations seen in primary
breast cancer. Moreover, more accurate modelling of the
in vivo tumour environment with 3D culture methods
allows the validation of founder (HRAS transformation)
and acquired (PIK3CA and TP53 mutations) events
that would not have been appreciated with traditional
techniques. The MCF10 progression series therefore
represents a good model with which to dissect potential
biomarkers and evaluate therapeutic targets involved in
the progression of breast cancer.
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